-
41
-
42
A Simple Machine Learning-Based Quantitative Structure–Activity Relationship Model for Predicting pIC<sub>50</sub> Inhibition Values of FLT3 Tyrosine Kinase
Published 2025-01-01“…<b>Background/Objectives:</b> Acute myeloid leukemia (AML) presents significant therapeutic challenges, particularly in cases driven by mutations in the FLT3 tyrosine kinase. This study aimed to develop a robust and user-friendly machine learning-based quantitative structure–activity relationship (QSAR) model to predict the inhibitory potency (pIC<sub>50</sub> values) of FLT3 inhibitors, addressing the limitations of previous models in dataset size, diversity, and predictive accuracy. …”
Get full text
Article -
43
-
44
REPEATED THERAPEUTIC LEUKAPHERESIS - A SOLE TREATMENT DURING PREGNANCY AS A BRIDGE BEFORE TYROSINE KINASE INHIBITORS FOR A PREGNANT WOMAN WITH CHRONIC MYELOGENOUS LEUKEMIA – A CASE REPORT AND DISCUSSION
Published 2025-01-01“…The mother achieved hematologic, cytogenetic and molecular remission within the next 6-9 months after initiation of tyrosine kinase inhibitor therapy. Discussion: The classical treatment for CML includes tyrosine kinase inhibitors, chemotherapy and/or allogeneic haematopoietic stem cell transplantation. …”
Get full text
Article -
45
Perbedaan Rerata Kadar Soluble Fms-Like Tyrosine Kinase-1 (Sflt-1) Serum pada Penderita Early Onset, Late Onset Preeklampsia Berat / Eklampsia dan Kehamilan Normal
Published 2016-01-01“…Kegagalan pengaturan dan ketidakseimbangan agen vasoaktif proangiogenik dan antiangiogenik plasenta, <em>soluble fms</em><em>-like tyrosine kinase</em>-1 (sFlt-1), <em>vascular endothelial growth factor</em> (VEGF) dan <em>placental growth factor</em> (PlGF) memainkan peran penting dalam patogenesis preeklampsia. …”
Get full text
Article -
46
Comparison of glycosylated fibronectin versus soluble fms-like tyrosine kinase/placental growth factor ratio testing for the assessment of pre-eclampsia: protocol for a multicentre diagnostic test accuracy study
Published 2025-02-01“…This study aimed to test the hypothesis that the sensitivity of the GlyFn test is not inferior to that of the current gold standard of soluble fms-like tyrosine kinase (sFlt)/PlGF-based laboratory testing for pre-eclampsia.Methods and analysis This is a multicentre prospective study. …”
Get full text
Article -
47
-
48
Different Activity of the Biological Axis VEGF-Flt-1 (fms-Like Tyrosine Kinase 1) and CXC Chemokines between Pulmonary Sarcoidosis and Idiopathic Pulmonary Fibrosis: A Bronchoalveolar Lavage Study
Published 2009-01-01“…We estimated the levels of vascular endothelial growth factor (VEGF) and its high-affinity receptor, Flt-1 (fms-like tyrosine kinase 1), in bronchoalveolar lavage fluid (BALF) of patients with IPF and pulmonary sarcoidosis. …”
Get full text
Article -
49
Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report
Published 2025-01-01Subjects: Get full text
Article -
50
A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality
Published 2024-03-01Subjects: Get full text
Article -
51
Real-world short-term outcomes and treatment regimen comparisons in patients with metastatic renal cell carcinoma treated with first-line immune combinations
Published 2025-01-01Subjects: “…Renal cell carcinoma; Tyrosine kinase inhibitor…”
Get full text
Article -
52
A Bibliometric Analysis of Medullary Thyroid Carcinoma From 2000 to 2022
Published 2024-07-01Subjects: Get full text
Article -
53
Vascular Endothelial Growth Factor (VEGF) Family and the Immune System: Activators or Inhibitors?
Published 2024-12-01Subjects: Get full text
Article -
54
-
55
Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination and its impact on immune responses in patients with chronic lymphocytic leukaemia
Published 2023-09-01“…This study aims to determine in patients with chronic lymphocytic leukaemia (CLL) if a 3-week pause in Bruton tyrosine kinase inhibitor therapy (BTKi) starting 1 week before delivery of SARS-CoV-2 vaccine booster, improves vaccine immune response when compared with continuation of BTKi.Methods and analysis An open-label, randomised controlled superiority trial will be conducted in haematology clinics in approximately 10 UK National Health Service (NHS) hospitals. …”
Get full text
Article -
56
Advanced breast cancer with pancreatic metastasis responding well to TKIs after ADC failure: Report of a rare case
Published 2025-02-01Subjects: Get full text
Article -
57
-
58
Editorial: Advances in immunotherapy of hepatic-biliary-pancreatic cancers, volume II
Published 2025-01-01Subjects: Get full text
Article -
59
-
60